Bris­tol My­ers cuts mid-stage NASH, an­ti-TIG­IT pro­grams

Bris­tol My­ers Squibb dis­closed Thurs­day at its R&D Day that it cut six pro­grams, in­clud­ing mid-stage drug can­di­dates for NASH and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.